Lupin has gained a head start over other generics firms aiming to enter the US market for Brovana (arformoterol tartrate) by launching an authorized generic version of the maintenance treatment for chronic obstructive pulmonary disease, months ahead of drug substance patents expiring.
Lupin Gets Head Start On Brovana With US Authorized Generic
Launches Authorized Version Of Sunovion’s Arformoterol Tartrate Inhalation Solution
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.
More from Products
More from Generics Bulletin
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.